Similar to Motzer et al (2002), who categorised IFN-α-treated advanced renal-cell cancer patients into three different groups with low (18%; overall survival 30 months), intermediate (62%; overall survival 14 months), and high-risk patients (20%; overall survival 5 months), respectively, we established three distinct survival subgroups that is, low-risk patients (38%) with an overall median survival of 32 months, intermediate-risk patients (47%) with an overall median survival of 18 months, and high-risk patients (15%) with an overall median survival of 8 months. The gene discussed is IFNA2; the disease is renal cell adenocarcinoma.